Home About Us Locations Services Your Visit Forms Patient


American Academy of Allergy Asthma and Immunology
American College of Allergy, Asthma and Immunology

Allergic Rhinitis


Asthma and Allergy Foundation of America
Instructions on How to Use Your Spacer for Kids
National Institute of Health - Asthma Resources for Kids
Allergy and Asthma Network - Mothers of Asthmatics
Children: Is your asthma controlled? Take this test!
Adults: Is your asthma controlled? Take this test!

Food Allergy

Current US Food Allergy Guidelines
Food Allergy and Anaphylaxis Network
Mothers of Children Having Allergies
Kids With Food Allergies
Traveling with Food Allergies
Medical ID Bracelet


Facts about Sinusitis
Overview of Sinusitis
Sinus Rinse | Netipot - It works!

Venom Allergy (bee/wasp sting)

Stinging Insect Facts

Latex Allergy

Resources for Latex Allergy

Skin Conditions

Drug Allergy

Eosinophilic Gastrointestinal Disorders

American Partnership for Eosinophilic Disorders

Immune Deficiency

Immune Deficiency Foundation

Celiac Disease and Gluten Sensitivity

University of Chicago - Celiac Disease Center
Gluten Free Blog
Gluten Free Recipes

Catch up on the latest allergy news from MedWorm.com

EpiPen maker settles federal claims for $465M a year after Sanofi filed suit
Mylan NV will pay $465 million fine to settle claims brought by the U.S. Justice Department that it overcharged the government for its emergency allergy drug, EpiPen. The U.S. Attorney’s Office in Massachusetts announced the agreement on Thursday, saying it had violated the False Claims Act “by knowingly misclassifying EpiPen, a branded epinephrine auto-injector drug, as a generic drug to avoid paying rebates owed to Medicaid.” French drug company Sanofi , the parent company of the state’s… (Source: bizjournals.com Health Care:Physician Practices headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

FDA Officials Look to Cut Cigarette Nicotine Levels
(MedPage Today) -- Commissioner and colleague outline framework for reduction strategy (Source: MedPage Today Allergy)
Mylan inks $465m settlement with DOJ over EpiPen Medicaid classification
Mylan (NSDQ:MYL) said today that it inked a $465 million deal with U.S. Dept. of Justice to settle claims that it misclassified its EpiPen allergy auto-injector device with the Medicaid Drug Rebate Program. In October last year, The Centers for Medicare & Medicaid Services said that Mylan had been overcharging Medicaid for its EpiPen device for years, despite being warned that it should have paid bigger rebates. Get the full story at our sister site, Drug Delivery Business News. The post Mylan inks $465m settlement with DOJ over EpiPen Medicaid classification appeared first on MassDevice. (Source: Mass Device)
Mylan, U.S. finalize $465 million EpiPen settlement
BOSTON (Reuters) - Mylan NV has finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases. (Source: Reuters: Health)
Peanut allergy treatment 'lasts up to four years'
Four years after children in a study took the oral treatment, 70% had no allergic reaction to peanuts. (Source: BBC News | Health | UK Edition)
Problems with the site? Please let us know.